Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1456-1466

  Smith, Ian C ^a   Heys, Steven D ^a   Hutcheon, Andrew W ^a   Miller, Iain D ^a   Payne, Simon ^a   Gilbert, Fiona J ^a   Ah See, Antoinne K ^a   Eremin, Oleg ^a   Walker, Leslie G ^a   Sarkar, Tarun K ^a   Eggleton, S Peter ^a   Ogston, Keith N ^a  

^a NHS GRAMPIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ONDANSETRON; PREDNISOLONE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; AXILLARY LYMPH NODE; BLOOD TOXICITY; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PREDNISOLONE; TAXOIDS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0037087562     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1456     Document Type: Article

References (67)

1. Primary chemotherapy in operable breast cancer
2. Primary chemotherapy in surgically resectable breast cancer
3. Primary chemotherapy for early breast cancer
4. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
5. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer
6. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomized trial - S6
7. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm
8. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
9. The efficacy of neoadjuvant chemotherapy compared to postoperative therapy in the treatment of locally advanced breast cancer
10. Breast tumours response to primary chemotherapy predicts local and distant control as well as survival
11. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer
12. Is primary chemotherapy useful for all patients with primary invasive breast cancer?
13. Treatment of large and locally advanced breast cancers using neo-adjuvant chemotherapy: Recurrence and survival
14. Clinical and pathological response to primary chemotherapy in operable breast cancer
15. Assessment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer
16. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
17. Anthracycline resistance in breast cancer: Clinical applications of current knowledge
18. Multidrug resistance in breast cancer: Is the jury in yet?
19. Multidrug resistance in breast cancer: A meta-analysis of MDR1/gp170 expression and its possible functional significance
20. Cellular resistance to anthracyclines
21. Reflections on the development of resistance during therapy for advanced breast cancer: Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients
22. Tamoxifen for early breast cancer: An overview of the randomised trials
23. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
24. Poly chemotherapy for early breast cancer: An overview of the randomised trials
25. Treatment of locally advanced breast cancer
26. Review of recent trials of chemotherapy for advanced breast cancer: The Taxanes
27. Integration of new therapies into the management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development
28. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
29. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: Preliminary results
30. Docetaxel (DOC) in heavily pretreated metastatic breast cancer (MBC): Analysis of an international compassionate-use trial
31. Randomized trial on preoperative dose-intensified adriamycin-docetaxel (ADOC) + tamoxifen in primary operable breast cancer
32. The efficacy of doxorubicin and docetaxel (Taxotere) in a phase II trial of neoadjuvant treatment of locally advanced breast cancer
33. Neoadjuvant chemotherapy with sequential doxorubicin (DOX) and docetaxel (DOC) in locally advanced breast cancer (LABC): A pilot study
34. GEPARDO (German preoperativc adriamycin docetaxel) trial comparing a combination dose-intensified adriamycin and docetaxel with or without tamoxifen as preoperative therapy in patients with operable breast cancer
35. Preoperative docetaxel/epirubicin (DE) in primary breast cancer
36. Phase II study of sequential docetaxel (Taxotere, TXT) and doxorubicin (DOX) as primary chemotherapy (CT) for large operable breast cancer (BC)
37. Induction chemotherapy in operable breast cancer: High pathological response rate induced by docetaxel
38. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
39. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer
40. Reporting results of cancer treatment
41. Diagnosis by needle core biopsy
42. New concepts in the management of primary breast cancer
43. Primary chemotherapy in breast cancer
44. Primary chemotherapy in breast cancer: Correlation between tumor response and patient outcome
45. Pathological response to neoadjuvant chemotherapy (CT): Final results of a prospective randomized trial of 4AT vs 4AC as induction therapy in patients with operable breast cancer using Sataloff classification
46. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
47. Neo-adjuvant high-dose weekly paclitaxel (HDWP) in stage IIB-IIIB breast cancer: A BRUOG study
48. Primary chemotherapy for operable breast cancer: High pathological response rate induced by docetaxel
49. Dose-dense chemotherapy with sequential doxorubicin (D) and docteaxel (Dt) for initial treatment of operable and inoperable stage II-IIIb breast cancer
50. Phase II trial combining docetaxel (D) doxorubicin (DOX) as neoadjuvant treatment in patients (Pts) with operable breast carcinoma (BC)
51. High pathological complete response (PCR) after neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer
52. Phase II study of doxorubicin and docetaxel as neoadjuvant therapy for women with stage IIB or III breast cancer
53. Phase II trial of primary chemotherapy with docetaxel and doxorubicin in locally advanced breast cancer: Clinical and pathological results
54. Results of the GEPARDO trial (German preoperative adriamycin docetaxel): A phase IIB study comparing the combination of dose-intensified adriamycin and docetaxel with or without tamoxifen in patients with operable breast cancer
55. Phase II study of doxorubicin, docetaxel, and 5-fluorouracil (FAT) in patients with locally advanced breast cancer
56. Phase I trial of weekly epirubicin/docetaxel (WED) in neoadjuvant treatment of operable breast cancer
57. High complete pathological response rate of locally advanced breast cancers (LABC) to neoadjuvant (NEO) docetaxel and cisplatin chemotherapy
58. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy
59. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma
60. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal foundation award lecture
61. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy
62. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer
63. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer
64. Pathological response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome
65. Dose, a critical factor in cancer chemotherapy
66. A gompertzian model of human breast cancer growth
67. Tumor size, sensitivity to therapy, and design of treatment schedules